Meeting
2020 ASCO Virtual Scientific Program
Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.
Authors
Drew W. Rasco
South Texas Accelerated Research Therapeutics, San Antonio, TX
Drew W. Rasco , Nehal J. Lakhani , Yuefen Tang , Hengbang Wang , Jiao Ji , Jason Chen , ZHIYAN LIANG , Alex Amaya , Dajun Yang , Yifan Zhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03386526
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3508)
DOI
10.1200/JCO.2020.38.15_suppl.3508
Abstract #
3508
Poster Bd #
238
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: John D. Powderly
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang